Henriques Ana Gabriela, Vieira Sandra Isabel, Rebelo Sandra, Domingues Sara C T S, da Cruz e Silva Edgar F, da Cruz e Silva Odete A B
Laboratório de Neurociências, Centro de Biologia Celular, Universidade de Aveiro, Aveiro, Portugal.
J Alzheimers Dis. 2007 Mar;11(1):85-95. doi: 10.3233/jad-2007-11112.
Alzheimer's amyloid-beta protein precursor (AbetaPP) can occur in different isoforms, among them AbetaPP(751), which is the most abundant isoform in non-neuronal tissues, and AbetaPP(695), often referred to as the neuronal isoform. However, few isoform-specific roles have been addressed. In the work here described, AbetaPP isoforms, both endogenous and as cDNA fusions with green fluorescent protein (GFP), were used to permit isoform-specific monitoring in terms of intracellular processing and targeting. Differences were particularly marked in the turnover rates of the immature isoforms, with AbetaPP(751) having a faster turnover rate than AbetaPP(695) (0.8 h and 1.2 h respectively for endogenous proteins and 1.1 h and 2.3 h for transfected proteins). Hence, AbetaPP(751) matures faster. Additionally, AbetaPP(751) responded to both okadaic acid (OA) and phorbol 12-myristate 13-acetate (PMA), as determined by sAbetaPP production, with PMA inducing a more robust response. For the AbetaPP(695) isoform, however, although PMA produced a strong response, OA failed to elicit such an induction in sAbetaPP production, implicating isoform specificity in phosphorylation regulated events. In conclusion, it seems that the AbetaPP(695) isoform is processed/metabolized at a slower rate and responds differently to OA when compared to the AbetaPP(751) isoform. The relevance of isoform-specific processing in relation to Alzheimer's disease needs to be further investigated, given the predominance of the AbetaPP(695) isoform in neuronal tissues and isoform-specific alterations in expression levels associated with the pathology.
阿尔茨海默病β淀粉样蛋白前体(AβPP)可呈现不同的异构体形式,其中AβPP(751)是在非神经组织中最丰富的异构体,而AβPP(695)常被称为神经元异构体。然而,很少有针对异构体特异性作用的研究。在本文所述的研究中,内源性AβPP异构体以及与绿色荧光蛋白(GFP)融合的cDNA被用于对细胞内加工和靶向进行异构体特异性监测。未成熟异构体的周转率差异尤为显著,AβPP(751)的周转率比AβPP(695)更快(内源性蛋白分别为0.8小时和1.2小时,转染蛋白分别为1.1小时和2.3小时)。因此,AβPP(751)成熟得更快。此外,通过可溶性AβPP(sAβPP)的产生来测定,AβPP(751)对冈田酸(OA)和佛波醇12 -肉豆蔻酸酯13 -乙酸酯(PMA)均有反应,PMA诱导的反应更强。然而,对于AβPP(695)异构体,虽然PMA产生了强烈反应,但OA未能在sAβPP产生中引发这种诱导,这表明在磷酸化调节事件中存在异构体特异性。总之,与AβPP(751)异构体相比,AβPP(695)异构体的加工/代谢速率似乎较慢,并且对OA的反应不同。鉴于AβPP(695)异构体在神经组织中的优势以及与病理学相关的异构体特异性表达水平改变,异构体特异性加工与阿尔茨海默病的相关性需要进一步研究。